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SUMMARY – Initial treatment of the majority of patients with diff erentiated thyroid cancer 
(DTC) includes total thyroidectomy. Postoperative ablation therapy with radioactive iodine (I-131) is 
indicated in all high-risk patients, however, there is disagreement regarding its use in low- and inter-
mediate-risk patients. Over the last few decades, thyroglobulin (Tg) has been established as the 
 primary biochemical tumor marker for patients with DTC. Th yroglobulin can be measured during 
thyroid hormone therapy or after thyroid-stimulating hormone (TSH) stimulation, through thyroid 
hormone withdrawal or the use of human recombinant TSH. In many studies, the cut-off  value for 
adequate Tg stimulation is a TSH value ≥30 mIU/L. However, there is an emerging body of evidence 
suggesting that this long-established standard should be re-evaluated, bringing this threshold into 
question. Recently, a risk stratifi cation system of response to initial therapy (with four categories) has 
been introduced and Tg measurement is one of the main components. Th e relationship between the 
Tg/TSH ratio and the outcome of radioiodine ablation has also been studied, as well as clinical 
 signifi cance of serum thyroglobulin doubling-time. Th e postoperative serum Tg value is an important 
prognostic factor that is used to guide clinical management, and it is the most valuable tool in long 
term follow-up of patients with DTC.
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Introduction
Th yroid cancer is the most common type of endo-
crine malignancy1. About 90% of thyroid neoplasms 
are diff erentiated thyroid cancers (DTC) with low ma-
lignant potential and a very good prognosis2. Over the 
last few decades, the incidence of thyroid cancer has 
considerably increased. Th e age-standardized inci-
dence rate of thyroid cancer has increased in Croatia 
22.1 times in women and 5.6 times in men in the pe-
riod from 1968 to 2014, with a decrease in mortality3. 
A similar trend has been observed around the world. 
In the United States, the yearly incidence has almost 
tripled from 4.9 in 1975 to 14.3 per 100,000 in 2009, 
without associated increase in mortality4. Th is per-
ceived increased incidence of DTC is mostly caused by 
more intensive imaging with neck ultrasonography 
(US) and the aggressive use of US guided fi ne needle 
aspiration biopsy (FNA), which has led to detection of 
disease in early stages5,6.
In the majority of patients with DTC, initial treat-
ment consists of total thyroidectomy. However, lobec-
tomy may be performed in patients with microcarci-
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noma without nodal metastases on imaging7,8. Postop-
erative ablation therapy with radioactive iodine (I-131) 
is indicated in all high-risk patients, however, there is 
disagreement regarding its indication and dosage in 
low- and intermediate-risk patients9-11. Th e introduc-
tion of L-levothyroxine substitution or suppression 
therapy is the next step in the treatment of these pa-
tients, which depends on balancing the degree of re-
sponse to initial therapy and increasing the risk of ad-
verse eff ects related to thyroid-stimulating hormone 
(TSH) suppression12. With this treatment approach, 
the majority of patients have an excellent prognosis 
with normal life expectancy13. However, in some pa-
tients, persistent disease is present after initial therapy, 
or disease recurrence is detected during follow-up.
Th yroglobulin (Tg) is a glycoprotein with a molec-
ular weight of approximately 660 kDa, which is synthe-
sized by thyrocytes and released into the lumen of thy-
roid follicles14. Production of Tg is stimulated by TSH, 
intrathyroidal iodine defi ciency or excess15, and the 
presence of thyroid-stimulating immunoglobulins. 
Th yroglobulin plays a crucial role in the synthesis of the 
peripheral thyroid hormones triiodothyronine (T3) 
and thyroxine (T4), containing tyrosine residues which 
are iodinated using tyrosine oxidase in monoiodotyro-
sine and diiodotyrosine forms (MIT and DIT), which 
then form T3 and T4. Over the last few decades, the 
role of Tg as the primary biochemical tumor marker in 
patients with DTC has been established. Serum Tg 
measurements, neck ultrasonography, and occasionally 
diagnostic I-131 whole body scintigraphy are used in 
the follow up of DTC patients16-18. Neck ultrasonogra-
phy is a readily available, noninvasive, cost-eff ective 
method, which can guide diagnostic procedures with 
low complication rates19. Recently, some authors have 
proposed the combined use of the above mentioned 
modalities with computed tomography (CT), magnetic 
resonance imaging (MRI), and positron emission to-
mography (PET) including [F18] FDG PET/CT 
when necessary11,20,21. Patients at low risk of disease re-
currence may be followed up only by neck US and se-
rum Tg measurement22.
Measurement of Th yroglobulin 
and Anti-Th yroglobulin Antibodies
Th yroglobulin has been measured by three diff er-
ent classes of methodology. Radioimmunoassay (RIA 
used since the 1970s), immunometric assay (IMA) 
since the 1980s, and liquid chromatography-tandem 
mass spectrometry (LC-MS/MS), which was devel-
oped in 2008. Immunometric assays are more sensitive 
than RIA and have shorter incubation time, wider 
working range and a stable labeled antibody reagent23.
Th e proposed functional sensitivity of current assays is 
≤0.1 μg/mL24. Serum Tg should be measured by vali-
dated immunoassays calibrated against the Certifi ed 
Reference Material (CRM 457, now described as 
BCR 457, European Commission, Institute for Refer-
ence Material and Method). Laboratories providing 
Tg measurements are required to participate in certi-
fi ed national or international programs of quality as-
surance. Ideally, follow-up of DTC patients with Tg 
and anti-thyroglobulin antibodies (TgAb) concentra-
tions should be performed in the same laboratory us-
ing the same assay each time24.
Anti-thyroglobulin antibodies are 330 kd mole-
cules which are often undetectable using older tech-
niques. Th e TgAb is polyclonal, belongs to the IgG 
class of antibodies, not restricted to a particular sub-
class, although IgG2 is the predominant class in 
DTC25. Anti-thyroglobulin antibodies falsely lower 
serum Tg in immunometric assays and are present in 
approximately 25% of thyroid cancer patients and 10% 
of the general population26,27. Th ey are the most serious 
problem that limits the clinical value of Tg determina-
tion. Anti-thyroglobulin antibodies should be mea-
sured in conjunction with serum Tg assay by the same 
method to increase accuracy. After total thyroidectomy 
and I-131 remnant ablation, TgAb usually disappear 
after 3 years in patients without persistent disease. 
Th yroglobulin antibody levels that decline over time 
are considered as a good prognostic sign, while rising 
levels, or a new appearance of TgAb increases the risk 
of persistent or recurrent disease28-31.
Preoperative Role of Th yroglobulin
Many studies have evaluated preoperative serum 
Tg values as a possible predictor of malignancy in thy-
roid nodules. Currently, the American Th yroid Asso-
ciation does not recommend routine preoperative 
measurement of serum Tg and TgAb since there is no 
defi nite evidence that this impacts patient manage-
ment or outcome. Meanwhile, the most recent EPIC 
study demonstrated a strong positive association be-
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tween thyroid cancer risk and blood levels of Tg, but 
did not support the use of serum Tg level for screening 
and early detection of DTC11,32.
Postoperative Measurement of Th yroglobulin
Th e half-life of serum Tg is 1-3 days, and the post-
operative nadir is reached in almost all patients 3-4 
weeks after operation33,34. After therapy with I-131, it 
takes several months for Tg to completely disappear 
from the circulation35. Th e measurement of Tg can be 
done during thyroid hormone therapy or after TSH 
stimulation, through thyroid hormone withdrawal or 
the use of human recombinant TSH (rhTSH)36-38. Re-
ports have questioned the possibility of a shorter dura-
tion of thyroid hormone withdrawal prior to Tg mea-
surement39. Recombinant human thyrotropin is ap-
proved in many countries for preparation of patients 
without distant metastases for radioiodine ablation. 
Th is exogenous method of elevating TSH levels may 
also be used in patients who are unable to achieve ad-
equate TSH elevation following thyroid hormone 
withdrawal, or in patients with signifi cant comorbi-
dities40. Th e rhTSH stimulated Tg levels tend to be 
lower than those following thyroid hormone with-
drawal11,41.
Cut-off  TSH Th reshold of 30 mIU/L
In many studies, the cut-off  value for adequate thy-
roglobulin stimulation is a TSH value ≥30 mIU/L11,42. 
Th is value has its diagnostic (elevation of Tg) and 
therapeutic (increased I-131 uptake in tumors) impli-
cations43. However, there is an emerging body of evi-
dence suggesting that this long-established standard 
should be re-evaluated, thus bringing this threshold 
into question. Although the value of TSH of 30 
mIU/L has been generally used in stimulation for 
I-131 ablation, some authors postulate diff erent values. 
For example, Vrachimis et al. published a report on pa-
tients who received ablation with TSH <30, with the 
same ablation outcome44. On the other hand, some au-
thors advocate the use of higher TSH values, suggest-
ing them to be connected with better treatment out-
come45,46. In our two previous studies, no diff erences 
were observed comparing TSH levels and the ablation 
outcome47,48.
Th yroglobulin and Radioiodine Ablation
Th e postoperative serum Tg value is an important 
prognostic factor that can be used to guide clinical man-
agement, especially in guiding the decision-making 
process leading to radioiodine ablation treatment, as 
well as predict successful ablation of the thyroid rem-
nant. Postoperative serum Tg values >10 ng/mL in-
crease the probability of persistent or recurrent disease, 
failing I-131 ablation, presence of distant metastases, 
and mortality, therefore prompting additional evalua-
tion and treatment49-52. It is very important to empha-
size that Tg level is not the only criterion for successful 
ablation, and that patient risk group should also be care-
fully considered. In low-risk patients, suppressed or 
stimulated Tg <1 ng/mL confi rms low recurrence 
risk51,53. In intermediate-risk patients, the same Tg val-
ues do not completely rule out the presence of small-
volume I-131-avid metastatic disease. In high-risk pa-
tients, even postoperative Tg values <1 ng/mL do not 
rule out RAI-avid disease and therefore do not infl u-
ence the decision to proceed with I-131 ablation11.
In conclusion, there is no optimal cut-off  for post-
operative serum Tg values to help determine indica-
tion for I-131 ablation in the American Th yroid As-
sociation (ATA) guidelines11. However, some authors 
recommend omission of I-131 ablation in patients 
with low postoperative stimulated (≤1 ng/mL) and 
non-stimulated Tg levels (0.2-0.3 ng/mL) with nega-
tive TgAb54-56. A recent study by Mourão et al. con-
cluded that patients with papillary thyroid carcinoma 
with low non-stimulated Tg levels (Tg <0.3 ng/mL) 
and negative nodal status in the neck following thy-
roidectomy did not require postoperative I-131 treat-
ment57. Th yroglobulin levels are especially important 
in patients from low- and intermediate-risk groups, 
where the selection of patients for adjuvant therapy 
can be made based on Tg values. Additionally, some 
studies addressed the correlation of postoperative se-
rum Tg values with success of remnant ablation; high-
er rates of ablation failure were observed with Tg val-
ues >5-6 ng/mL regardless of I-131 activity58,59.
Th yroglobulin/Th yrotropin Ratio as a Predictive 
Factor for Radioiodine Ablation Outcome
In recent literature, the relationship between thyro-
globulin/thyrotropin ratio and the outcome of radioio-
dine ablation has been extensively studied. For exam-
M. Prpić et al. Th yroglobulin in thyroid cancer
Acta Clin Croat, Vol. 57, No. 3, 2018 521
ple, Trevizam et al. bring into question the hypothesis 
that thyroglobulin levels and the thyroglobulin/thyro-
tropin ratio may accurately predict the success of ra-
dioiodine ablation therapy in patients with DTC. Th e 
Tg and Tg/TSH ratio cut-off  values that predicted 
success of I-131 therapy were 4.41 ng/mL and 0.093, 
respectively. After multivariate analysis, only serum Tg 
emerged as an independent factor predicting ablation 
outcomes60. Further evidence for Tg/TSH as a predic-
tive factor was confi rmed in studies assessing radioio-
dine ablation failure and the need for re-ablation in 
low- and intermediate-risk groups of patients48,61. For 
example, one study evaluated 740 such patients, with 
the Tg/TSH ratio determined to be a more powerful 
prognostic factor than Tg alone, and higher Tg/TSH 
ratios were found to be an independent predictor of 
treatment failure in a multivariate logistic regression 
analysis. Patients with Tg/TSH >0.126 had a higher 
probability of radioiodine ablation failure48.
In another study, which compared Tg and Tg/TSH 
ratio, also in low and intermediate groups of patients, 
and re-ablation outcomes, TSH signifi cantly increased, 
Tg decreased, and Tg/TSH ratio decreased from 
0.115±0.217 to 0.034±0.071 prior to re-ablation. A 
positive association was observed between treatment 
failure and Tg2 levels, as well as between treatment 
failure and Tg2/TSH2 ratio61. In a study by Lin et al., 
the Tg/TSH ratio was considered as a predictive factor 
for treatment failure in patients with DTC62. Further 
studies are needed to evaluate the predictive and prog-
nostic value of this easy calculable variable in patients 
undergoing TSH stimulation.
Value of Th yroglobulin 
in Dynamic Risk Stratifi cation
Th e 2015 ATA guidelines have classifi ed patients 
with DTC into low-, intermediate- and high-risk 
groups11. Th e risk of recurrence is associated with risk 
stratifi cation, with the risk of recurrence in the ATA 
intermediate-risk group ranging from 3% to 9%, while 
the risk of recurrence in ATA high-risk patients ranges 
from 23% to 40%. However, the initially estimated re-
currence risk should be continually modifi ed during 
follow up, since it can change over time as a function 
of disease status and response to therapy11,63. Th e ma-
jority of DTC patients show elevated preoperative Tg, 
but the predictive role has not been clearly outlined, 
since immunoassays cannot diff erentiate between Tg 
secreted by normal tissue and by malignant thyroid 
cancer cells64.
All patients with high-risk according to ATA 
should receive I-131 treatment, as this therapy im-
proves both disease-free and disease-specifi c survival. 
In ATA low-risk patients with tumor size ≤1 cm, there 
is no indication for postoperative I-131 ablation ther-
apy. However, in low-risk group patients with other 
risk factors, as well as in ATA intermediate-risk pa-
tients data regarding indications for I-131 ablation are 
confl icting, and therefore I-131 ablation therapy is se-
lectively utilized11. Th e response to initial therapy (with 
four categories of treatment response) was introduced 
by Tuttle et al. and modifi ed in another study by Vais-
man et al.65,66. Th yroglobulin measurement is one of 
the main factors in “response to therapy reclassifi ca-
tion” in patients receiving radioiodine remnant abla-
tion after total thyroidectomy11.
Patients with suppressed Tg <0.2 ng/mL, TSH 
stimulated Tg <1 ng/mL, and with negative imaging 
studies fall into the excellent response to therapy sub-
group, with a very low risk of recurrence, and almost 
no disease-specifi c mortality65,67-69. Th e “biochemical 
incomplete response” category includes patients with 
negative imaging studies, but with elevated Tg levels 
following treatment (suppressed Tg ≥1 ng/mL or 
stimulated Tg ≥10 ng/mL), or with rising TgAb val-
ues. Th e mortality rate in this subgroup is minimal, but 
a signifi cant number of patients in this group develop 
structural disease recurrence65,70.
In the group with functional or structural evidence 
of disease (structural incomplete response), the Tg 
level and the presence (or absence) of TgAb do not 
change the response classifi cation of these patients. 
Th e indeterminate response group includes patients 
with biochemical or structural fi ndings that cannot be 
classifi ed as either benign or malignant. Patients with 
non-stimulated detectable levels (Tg <1 ng/mL), or 
stimulated Tg detectable levels (Tg <10 ng/mL) fall 
into this subgroup. Th e patients with stable or declin-
ing anti-Tg antibodies without structural or functional 
disease are part of this “response” group65,70.
Th yroglobulin in Long-Term Follow-up 
of Patients with Diff erentiated Th yroid Cancer
Long-term monitoring of patients with DTC is 
guided by the patient’s response to therapy during the 
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fi rst year of follow-up. Most cases with recurrences of 
DTC occur during the fi rst years of follow-up, but 
may occasionally also occur many years after initial 
treatment71. At each follow-up, clinicians reclassify 
ongoing management recommendations in accordance 
with the patient’s current clinical status. Detection of 
the possible persistent or recurrent disease during the 
fi rst year after thyroidectomy is obtained with neck ul-
trasonography and measurement of TSH, as well as 
serum Tg levels. Additional imaging such as MRI, 
CT72, and FDG-PET-CT73 is usually reserved for 
high-risk patients who typically have either biochemi-
cal or structural incomplete response to initial therapy 
and follow-up of intermediate-risk patients who dem-
onstrate structural or biochemical incomplete response 
to treatment during the fi rst year of follow-up. Diag-
nostic I-131 whole body scintigraphy has a role in the 
follow-up of these patients with high or intermediate 
risk of disease, but not in the follow-up of low-risk 
patients.
Serum Tg and TgAb in patients on thyroid hor-
mone suppression are generally measured every 3 to 6 
months for the fi rst year following initial treatment. 
Th e interpretation of serum Tg depends on the type of 
initial therapy. For patients with total thyroidectomy 
and radioiodine remnant ablation, non-stimulated Tg 
should be <0.2 ng/mL and stimulated Tg <1 ng/mL in 
the absence of interfering antibodies. In patients with 
lobectomy, serum Tg levels are less useful because they 
will not refl ect the presence or absence of malignant 
tissue, but will depend on the remaining thyroid lobe 
volume, current iodine status and TSH concentration. 
In these patients, follow-up is performed by neck ul-
trasonography and, when necessary, US-guided fi ne 
needle aspiration (FNA) of any suspected metastatic 
foci24.
Neck US is performed at 6- to 12-month intervals 
depending on the patient’s risk stratifi cation. Cervical 
lymph nodes are the most common site of recurrence 
in patients with papillary carcinoma. Th e most sensi-
tive technique for localization of recurrent tumor in 
the neck is US. Metastatic lymph nodes on US dem-
onstrate a cystic appearance, microcalcifi cations, bulg-
ing shape, loss of normal hilum, and peripheral vascu-
larization19,74. US-guided FNA of suspected lymph 
nodes with Tg measurement in aspirates (FNA-Tg) 
should be performed in patients with suspected nodal 
metastases19. Values under 1 ng/mL are considered 
normal, values of 1-10 ng/mL should be compared 
with the results of cytology, and values above 10 ng/
mL suggest the presence of malignancy19. Some au-
thors suggest comparison of FNA-Tg and serum Tg 
levels as worthwhile. FNA-Tg is highly reliable in the 
diagnosis of neck nodal metastases75.
Serum Tg may fail to identify patients with a rela-
tively small volume of metastatic disease. Th ese small 
metastases are often located in the neck region and US 
is the method of choice for detection of nodal disease 
in these patients11. In cases with elevated serum Tg 
levels and negative radioiodine scan, the explanation 
for such fi ndings could be the presence of tumor de-
posits too small to be detected by a scintillation cam-
era, or loss of iodine uptake through tumor de-diff er-
entiation76. In such patients, neck ultrasound and 
neck/chest CT may be performed in order to detect 
metastatic disease. If negative, other imaging methods 
should be performed. In high-risk patients and in 
those with serum Tg >10 ng/mL, [18F]-FGD PET/
CT should also be performed73,77.
Th yroglobulin Doubling Time
In medullary thyroid cancer, measurements of se-
rum calcitonin and carcinoembryonic antigen (CEA) 
doubling-times have prognostic implications78,79. Miy-
auchi et al. have described the prognostic impact of 
serum Tg doubling time (Tg-DT) during follow up 
and under thyrotropin suppression. In this study, pa-
tients were divided into several groups: Tg-DT <1 
year, 1-3 years, and ≥3 years. In the group with a Tg-
DT of <1 year, disease-specifi c survival at 10 years was 
50%, in the group with Tg-DT of 1-3 years it was 
95%, and in other groups disease-specifi c survival was 
100%. Th yroglobulin DT was found to be a statisti-
cally signifi cant indicator of survival by univariate 
analysis. Multivariate analysis also revealed Tg-DT to 
be an independent predictor of distant metastases and 
loco-regional treatment failure80.
Several studies addressed the issue of advanced/re-
current thyroid cancer and Tg-DT values. In a study 
by Rossling et al., the Tg-DT and other prognostic 
markers in patients with recurrent/progressive DTC 
were evaluated in uni- and multivariate analysis. Th e 
median observed Tg-DT was 212 days. Mortality risk 
was two times higher in patients with Tg-DT <5 
months as compared with patients with Tg-DT >14 
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months81. In a study by Giovanella et al., the predictive 
value of Tg and Tg-DT on positive [18F]-FDG PET/
CT scan in patients with biochemical recurrence of 
DTC was assessed. Serum Tg levels were higher in pa-
tients with positive [18F]-FDG PET/CT scan as 
compared to patients with negative PET/CT, and the 
authors concluded that the accuracy of [18F]-FDG 
PET/CT signifi cantly improved with serum Tg levels 
>5.5 ng/mL during levothyroxine treatment, or with 
Tg-DT <1 year82.
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Sažetak
TIREOGLOBULIN: TUMORSKI BILJEG DIFERENCIRANIH KARCINOMA ŠTITNJAČE 
– KLINIČKA RAZMATRANJA
M. Prpić, M. Franceschi, M. Romić, T. Jukić i Z. Kusić
Početno liječenje većine bolesnika s diferenciranim karcinomom štitnjače uključuje kirurško odstranjenje štitnjače. 
 Poslijeoperacijsko liječenje radioaktivnim jodom (I-131) indicirano je u većine visokorizičnih bolesnika, dok je primjena 
I-131 u bolesnika niskog i srednjeg rizika predmet rasprave. U prethodnih nekoliko desetljeća tireoglobulin (Tg) je prihvaćen 
kao primarni biokemijski tumorski biljeg visoke osjetljivosti i specifi čnosti u bolesnika s diferenciranim karcinomom štitnja-
če. Mjerenje Tg može se izvoditi tijekom uzimanja hormonske terapije L-tiroksinom ili uz stimulaciju tireotropinom (TSH). 
Stimulacija putem TSH može se postići prekidom hormonske terapije L-tiroksinom ili uz primjenu rekombinantnog huma-
nog TSH (rhTSH). Dugi niz godina se granična vrijednost TSH ≥30 mIU/L smatrala zadovoljavajućom za stimulaciju Tg, 
međutim, novije spoznaje osporavaju tu granicu i zahtijevaju nova istraživanja i preporuke. Nedavno je uvedena podjela 
 bolesnika u 4 rizične skupine ovisno o odgovoru na liječenje jodom-131 nakon totalne tireoidekotmije, a mjerenje Tg jedna 
je od glavnih odrednica podjele. U posljednje vrijeme se značenje pridaje omjeru Tg-TSH u predviđanju ishoda ablacije 
 jodom-131, kao i prognostičko značenje vremena udvostručenja Tg. Poslijeoperacijska serumska vrijednost Tg je važan 
 prognostički čimbenik i odrednica daljnjeg liječenja, a određivanje Tg je osnovna metoda dugoročnog praćenja bolesnika s 
diferenciranim karcinomom štitnjače.
Ključne riječi: Tireoglobulin; Tireoidni tumori; Tireoidektomija; Jod, radioizotopi; Tumorski biljezi, biološki; Tireoidni hormo-
ni; Hrvatska
